Kerob Delphine, Czermanska Anna, Karamon Ewa M, Moga Alain, Lecerf Guillaume, Nioré Margot, Le Dantec Guénaëlle, Le Floc'h Caroline, Tan Jerry
Scientific Direction, La Roche-Posay Laboratoire Dermatologique, Levallois-Perret, France.
Dermascan, Poland Sp. z o. o., Gdansk, Poland.
Clin Cosmet Investig Dermatol. 2023 Jul 11;16:1787-1794. doi: 10.2147/CCID.S418483. eCollection 2023.
Intolerance to dermocosmetics is frequent in subjects with allergic contact dermatitis (ACD). A dermocosmetic (DC) was developed to restore the natural skin barrier, to reduce skin inflammation and to improve sensitive skin in ACD.
To assess the benefit of a DC in subjects with an allergic background and intolerance to cosmetic care, or with sensitive skin.
In this open-label study, 107 subjects above 16 years of age applied DC on the face twice a day for 28 days. Assessments at Days 0, 14 and 28, included skin sensitivity, stinging test, local tolerance, transepidermal water loss (TEWL), skin hydration, inflammatory biomarkers (IL-1α, IL-1RA, PGE2) using tape stripping and subject satisfaction.
88% were women and mean age was 42.0±15.0 years. Skin sensitivity at inclusion scored 5.9±0.35; 46% had ACD, 95% skin irritation, 92% sensitive skin and 88% intolerance to cosmetics. A significant (p<0.0001) 85% decrease of frequency and intensity of the composite score was observed at both endpoints. Stinging scores significantly (p<0.0001) decreased from 3.9 at baseline to 2.4 at Day 14 and 1.4 at Day 28; 77% and 81% of subjects reported improved skin reactivity at Day 14 and Day 28, respectively. Similar improvements were noted in the frequency and intensity of irritation, erythema, stinging, burning and discomfort. TEWL, skin hydration and inflammatory biomarker levels significantly (p<0.0001) improved. Overall subject satisfaction (85%) and tolerance (investigators: 99%, subjects: 97%) were high.
DC significantly reduced the frequency and intensity of facial skin intolerability and sensitivity in subjects with skin intolerant to skin care products.
NCT05487937.
在过敏性接触性皮炎（ACD）患者中，对皮肤护理化妆品不耐受的情况很常见。研发了一种皮肤护理化妆品（DC），以恢复天然皮肤屏障、减轻皮肤炎症并改善ACD患者的敏感性皮肤。
评估DC对有过敏背景且对化妆品护理不耐受或有敏感性皮肤的患者的益处。
在这项开放标签研究中，107名16岁以上的受试者每天在面部涂抹DC两次，持续28天。在第0天、第14天和第28天进行评估，包括皮肤敏感性、刺痛试验、局部耐受性、经表皮水分流失（TEWL）、皮肤水合作用、使用胶带剥离法检测炎症生物标志物（IL-1α、IL-1RA、PGE2）以及受试者满意度。
88%为女性，平均年龄为42.0±15.0岁。纳入时皮肤敏感性评分为5.9±0.35；46%患有ACD，95%有皮肤刺激，92%为敏感性皮肤，88%对化妆品不耐受。在两个终点时，综合评分的频率和强度均显著降低（p<0.0001），降幅达85%。刺痛评分从基线时的3.9显著降低（p<0.0001）至第14天的2.4和第28天的1.4；分别有77%和81%的受试者报告在第14天和第28天皮肤反应性有所改善。在刺激、红斑、刺痛、灼痛和不适感的频率和强度方面也有类似改善。TEWL、皮肤水合作用和炎症生物标志物水平显著改善（p<0.0001）。总体受试者满意度较高（85%），耐受性也较高（研究者：99%，受试者：97%）。
DC显著降低了对护肤品不耐受的受试者面部皮肤不耐受和敏感性的频率及强度。
NCT05487937。
